Questions and answers on the review of Tysabri (natalizumab)

 

Socialized medicine

Questions and answers on the review of Tysabri (natalizumab)

The European Medicines Agency has completed a review of Tysabri (natalizumab) at the request of the European Commission, following concerns over the safety of the medicine. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefits of Tysabri continue to outweigh its risks, but has recommended that a number of measures be put in place to manage the risk of the brain infection progressive multifocal leukoencephalopathy (PML) and to make sure that patients and doctors are aware of this risk.

Responder

Por favor, inicia sesión con uno de estos métodos para publicar tu comentario:

Logo de WordPress.com

Estás comentando usando tu cuenta de WordPress.com. Cerrar sesión / Cambiar )

Imagen de Twitter

Estás comentando usando tu cuenta de Twitter. Cerrar sesión / Cambiar )

Foto de Facebook

Estás comentando usando tu cuenta de Facebook. Cerrar sesión / Cambiar )

Google+ photo

Estás comentando usando tu cuenta de Google+. Cerrar sesión / Cambiar )

Conectando a %s